Skip to main content

Pharmacokinetic-pharmacodynamic analysis of fluoroquinolones against Bacillus anthracis


Based on the pharmacokinetic-pharmacodynamic (PK-PD) parameters of ciprofloxacin in rhesus monkeys, the efficacies of levofloxacin, sparfloxacin, norfloxacin, and tosufloxacin against anthrax in humans were examined. The optimal PK-PD parameter for the prophylaxis or treatment of infection with Bacillus anthracis is not clearly defined. To evaluate the efficacy of fluoroquinolones against anthrax, PK-PD parameters and the protein-binding effect of fluoroquinolones are used. B. anthracis is very susceptible to fluoroquinolones in vitro, and levofloxacin, sparfloxacin, and tosufloxacin may be as effective against anthrax as ciprofloxacin by PK-PD analysis. However, additional studies of the in vivo model are necessary to define more clearly efficacy against anthrax and the pharmacodynamic relationship of fluoroquinolones.

This is a preview of subscription content, access via your institution.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Tetsunari Kihira.

About this article

Cite this article

Kihira, T., Sato, J. & Shibata, T. Pharmacokinetic-pharmacodynamic analysis of fluoroquinolones against Bacillus anthracis . J Infect Chemother 10, 97–100 (2004).

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI:

Key words

  • Fluoroquinolones
  • Anthrax
  • Pharmacokinetics
  • Pharmacodynamics